These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

184 related items for PubMed ID: 11062363

  • 21. Biochemical response after 3-d conformal radiotherapy of localized prostate cancer to a total dose of 66 gy 4-year results.
    Wachter-Gerstner N, Wachter S, Goldner G, Nechvile E, Pötter R.
    Strahlenther Onkol; 2002 Oct; 178(10):542-7. PubMed ID: 12386785
    [Abstract] [Full Text] [Related]

  • 22. Androgen deprivation induces human prostate epithelial neuroendocrine differentiation of androgen-sensitive LNCaP cells.
    Yuan TC, Veeramani S, Lin FF, Kondrikou D, Zelivianski S, Igawa T, Karan D, Batra SK, Lin MF.
    Endocr Relat Cancer; 2006 Mar; 13(1):151-67. PubMed ID: 16601285
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. The change in the dihydrotestosterone level in the prostate before and after androgen deprivation therapy in connection with prostate cancer aggressiveness using the Gleason score.
    Nishiyama T, Ikarashi T, Hashimoto Y, Wako K, Takahashi K.
    J Urol; 2007 Oct; 178(4 Pt 1):1282-8; discussion 1288-9. PubMed ID: 17698092
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. [Loss of differentiation of a prostate adenocarcinoma after hormone therapy: the example of a metastasis in the spongy body of the penis].
    Uphoff J, Woziwodzki J, Schattka SO, Kollias A.
    Aktuelle Urol; 2008 Sep; 39(5):373-7. PubMed ID: 18798127
    [Abstract] [Full Text] [Related]

  • 29. Changes in chromogranin a serum levels during endocrine therapy in metastatic prostate cancer patients.
    Sasaki T, Komiya A, Suzuki H, Shimbo M, Ueda T, Akakura K, Ichikawa T.
    Eur Urol; 2005 Aug; 48(2):224-9; discussion 229-30. PubMed ID: 16005374
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Biologic agents as adjunctive therapy for prostate cancer: a rationale for use with androgen deprivation.
    Nelson EC, Cambio AJ, Yang JC, Lara PN, Evans CP.
    Nat Clin Pract Urol; 2007 Feb; 4(2):82-94. PubMed ID: 17287869
    [Abstract] [Full Text] [Related]

  • 40. 1alpha,25-Dihydroxyvitamin D3 down-regulates expression of prostate specific membrane antigen in prostate cancer cells.
    Serda RE, Bisoffi M, Thompson TA, Ji M, Omdahl JL, Sillerud LO.
    Prostate; 2008 May 15; 68(7):773-83. PubMed ID: 18247401
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.